Nuvation Bio Inc.
Symbol: NUVB (NYSE)
Company Description:
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
- Today's Open: $3.48
- Today's High: $4.081
- Today's Low: $3.401
- Today's Volume: 22.01M
- Yesterday Close: $3.42
- Yesterday High: $3.48
- Yesterday Low: $3.15
- Yesterday Volume: 12.01M
- Last Min Volume: 111
- Last Min High: $3.915
- Last Min Low: $3.915
- Last Min VWAP: $3.915
- Name: Nuvation Bio Inc.
- Website: https://www.nuvationbio.com
- Listed Date: 2021-02-10
- Location: SAN FRANCISCO, CA
- Market Status: Active
- CIK Number: 0001811063
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.33B
- Round Lot: 100
- Outstanding Shares: 342.27M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-08-13 | 4 | View |
2025-08-07 | 10-Q | View |
2025-08-07 | 8-K | View |
2025-07-17 | SCHEDULE 13G | View |
2025-06-18 | 4 | View |
2025-06-18 | 4 | View |
2025-06-18 | 4 | View |
2025-06-18 | 4 | View |
2025-06-18 | 4 | View |
2025-06-11 | 8-K | View |
2025-05-23 | 4 | View |
2025-05-23 | 4 | View |
2025-05-23 | 4 | View |
2025-05-23 | 4 | View |
2025-05-23 | 4 | View |
2025-05-23 | 8-K | View |
2025-05-12 | SCHEDULE 13G/A | View |
2025-05-07 | 10-Q | View |
2025-05-07 | 8-K | View |
2025-05-06 | 4 | View |